12:00 AM
 | 
Mar 15, 1999
 |  BC Week In Review  |  Company News  |  Deals

Techniclone, Biotechnology Development Ltd., Schering deal

TCLN exercised its option to reacquire from Biotechnology Development European and other marketing rights to its Oncolym radiolabeled monoclonal antibody for a combination of TCLN stock, warrants and...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >